Ars Pharmaceuticals Inc (SPRY) financials
Ars Pharmaceuticals revenue and earnings by year
Ars Pharmaceuticals's revenue was $84.3 million in the fiscal year to December 31, 2025, down 5.5% from the year before. Net income was -$171 million, -203.3% of revenue. Since the fiscal year to December 31, 2021, revenue has grown 97.8% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 5 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 84 | 89 | 0 | 1 | 6 |
| Revenue growth | -5.5% | 297063.3% | -97.7% | -76.1% | — |
| Gross profit | 64 | 88 | — | — | — |
| Gross margin | 75.8% | 98.9% | — | — | — |
| Operating income | -179 | -3 | -68 | -36 | -19 |
| Operating margin | -212.9% | -3.5% | -225066.7% | -2698.8% | -353.3% |
| Net income | -171 | 8 | -54 | -35 | -20 |
| Net margin | -203.3% | 9.0% | -181216.7% | -2635.4% | -367.7% |
| Diluted EPS | -$1.74 | $0.08 | -$0.57 | -$0.87 | -$0.70 |
| Free cash flow | -171 | 13 | -59 | -40 | -18 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SPRY in Markets.
How Ars Pharmaceuticals makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Product | $26.2M | 77.9% |
| Revenue Under Supply Agreements | $7.39M | 22.0% |
| Revenue Under Collaboration Agreements | $57.0K | 0.2% |
See also: SPRY returns
No forecast, no recommendation. This page describes Ars Pharmaceuticals Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.